Transgene Presents Promising New Data from its Next-Generation Immunotherapy Platforms at AACR 2020
22 Junho 2020 - 10:15AM
Business Wire
Regulatory News:
Transgene (Paris:TNG), a biotech company that designs and
develops virus-based immunotherapies for the treatment of
cancer, presents its broad viral vector expertise and their
potential to transform the fight against cancer at the AACR 2020
Virtual Annual Meeting II.
myvac® Transgene presents data demonstrating that the
prediction algorithm used to customize TG4050 for each patient is
accurate at identifying immunogenic cancer mutations even among a
large set of candidate tumor mutations. The poster is entitled:
“Performance of neoantigen prediction for the design of TG4050, a
patient specific neoantigen cancer vaccine” (#4566)
- Because only 1 to 5% of tumor mutations are immunogenic, they
can be particularly difficult to identify. To demonstrate the
accuracy of the prediction algorithm, Transgene and NEC analyzed 6
tumor samples from patients with non-small cell lung cancer
eligible for tumor resection. NSCLC are highly mutated tumors that
thus generated a massive amount of data that proved compatible with
the machine learning approach.
- More than 86% of top ranked peptides identified were
immunogenic. The NEC/Transgene prediction system was also able to
identify immunogenic peptides that were missed by netMHCpan 4.0,
the industry standard predictor.
- These results demonstrate that the specificity of our approach
outperforms the industry standard and are expected to translate in
enhanced activity in patients.
- Two PoC Phase 1 clinical trials evaluating TG4050, the first
therapeutic vaccine leveraging this algorithm, are ongoing in the
USA and in Europe.
The poster can be downloaded on the AACR website and here.
___________________
Invir.IOTM
Transgene is presenting preclinical data on two oncolytic
viruses derived from the Invir.IO™ platform, the clinical-stage
BT-001 and the new candidate TG6010.
BT-001 Transgene and
BioInvent are presenting a poster that supports the clinical
development of BT-001, an anti-CTLA4 antibody-encoding oncolytic
virus, against solid tumors: “BT-001, an oncolytic Vaccinia
virus armed with a Treg-depletion-optimized recombinant human
anti-CTLA4 antibody and GM-CSF to target the tumor
microenvironment.” (#5602)
- Cure rates exceeding 70% were seen in multiple mouse models,
demonstrating the powerful therapeutic effect of BT-001 when used
as a single agent, providing a solid basis for BT-001’s upcoming
clinical development, with a Phase 1 clinical trial expected to
start before the end of 2020.
- The anti-CTLA-4 antibody and GM-CSF accumulate in tumors with
low systemic exposure. Concentrations of the anti-CTLA-4 antibody
in the tumor after intratumoral injection of BT-001 is more than
10-fold higher than after intraperitoneal injection of 3 mg/kg of
the recombinant antibody in a xenograft tumor model.
- When tumor cells were re-implanted in mice that had been cured
after a first BT-001 treatment, a strong tumor-specific response
and long-lasting immune memory were developed by these mice.
- BT-001, even at sub-optimal dose, reinforced the therapeutic
activity of anti-PD-1 treatment – opening up potential combinations
for powerful dual checkpoint blockade treatment regimens
The poster can be downloaded on the AACR website and here.
More details are available in the press release distributed
simultaneously and available on www.transgene.fr.
TG6010 Transgene is also
presenting preclinical data obtained with TG6010, an Invir.IO™
based oncolytic virus encoding human cytidine deaminase (hCD) in a
poster entitled: “Oncolytic Vaccinia Virus expressing Cytidine
Deaminase induces DNA damage and shows potent anti-tumor
effects” (#4576)
- In addition to the intrinsic properties of the Invir.IO™ viral
vector (superior oncolysis, immunogenic cell death, stimulation of
innate and adaptive immune responses), TG6010 directly expresses
hCD in the tumor micro-environment.
- hCD is an enzyme that converts cytidine into uridine. Cytidine
being one of the 4 nucleotides that compose DNA, it is absolutely
necessary to enable cell replication and tumor progression.
- By expressing hCD in the tumor, TG6010 will indirectly deprive
cancer cells from the material they need to replicate, leading to
DNA instability and ultimately cell death (apoptosis).
- The preclinical data presented at AACR also show that the
activity of TG6010 is associated with a significant decrease of
available cytidine in the plasma, which resulted in a distant
antitumor effect.
- Additional experiments are being conducted to further assess
the potential of TG6010 as a single agent and in combination with
other treatments that target tumor cells DNA, and DNA repair
mechanisms.
The poster can be downloaded on the AACR website and here.
***
About Transgene Transgene (Euronext: TNG) is a publicly
traded French biotechnology company focused on designing and
developing targeted immunotherapies for the treatment of cancer.
Transgene’s programs utilize viral vector technology with the goal
of indirectly or directly killing cancer cells. The Company’s
clinical-stage programs consist of two therapeutic vaccines (TG4001
for the treatment of HPV-positive cancers, and TG4050, the first
individualized therapeutic vaccine based on the myvac® platform) as
well as two oncolytic viruses (TG6002 for the treatment of solid
tumors, and BT-001, the first oncolytic virus based on the
Invir.IO™ platform). With Transgene’s myvac® platform, therapeutic
vaccination enters the field of precision medicine with a novel
immunotherapy that is fully tailored to each individual. The myvac®
approach allows the generation of a virus-based immunotherapy that
encodes patient-specific mutations identified and selected by
Artificial Intelligence capabilities provided by its partner NEC.
With its proprietary platform Invir.IO™, Transgene is building on
its viral vector engineering expertise to design a new generation
of multifunctional oncolytic viruses. Transgene has an ongoing
Invir.IO™ collaboration with AstraZeneca. Additional information
about Transgene is available at: www.transgene.fr. Follow us on
Twitter: @TransgeneSA
Disclaimer This press release contains forward-looking
statements, which are subject to numerous risks and uncertainties,
which could cause actual results to differ materially from those
anticipated. The occurrence of any of these risks could have a
significant negative outcome for the Company’s activities,
perspectives, financial situation, results, regulatory authorities’
agreement with development phases, and development. The Company’s
ability to commercialize its products depends on but is not limited
to the following factors: positive pre-clinical data may not be
predictive of human clinical results, the success of clinical
studies, the ability to obtain financing and/or partnerships for
product manufacturing, development and commercialization, and
marketing approval by government regulatory authorities. For a
discussion of risks and uncertainties which could cause the
Company’s actual results, financial condition, performance or
achievements to differ from those contained in the forward-looking
statements, please refer to the Risk Factors (“Facteurs de Risque”)
section of the Universal Registration Document, available on the
AMF website (http://www.amf-france.org) or on Transgene’s website
(www.transgene.fr). Forward-looking statements speak only as of the
date on which they are made and Transgene undertakes no obligation
to update these forward-looking statements, even if new information
becomes available in the future.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200622005360/en/
Transgene: Lucie Larguier Director Corporate
Communications & IR +33 (0)3 88 27 91 04
investorrelations@transgene.fr
Media: Citigate Dewe Rogerson David Dible/Sylvie
Berrebi + 44 (0)20 7638 9571 transgene@citigatedewerogerson.com
Transgene (EU:TNG)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Transgene (EU:TNG)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024